Objectives: This study ascertained the regulation of the stem cell marker CD133 and its potential applicability for prognostication of gastrointestinal stromal tumors (GISTs).
quantitative polymerase chain reaction.
Results: The expression of hypermethylated CD133 could be reactivated in the GIST cell line upon hypomethylation with the drug. Similarly, in patient material, CD133 methylation percentage correlated inversely with the protein expression and reflected tumor size with hypermethylation in small (<2 cm) tumors and virtually no methylation in large (>10 cm) GISTs. The gene's methylation percentage and expression level were clearly specific to anatomic sites and distinct driver mutations. KIT-mutant gastric GISTs exhibited significantly lower methylation degrees and concomitant high CD133 protein abundance compared with KIT-mutant GISTs from the small intestine. CD133 hypermethylation was documented in PDGFRA-mutant gastric GISTs along with low CD133 expression compared with KIT-mutant gastric GISTs. High CD133 expression was a prognosticator of shorter disease-free survival in all patients. In a subgroup of KIT-mutant gastric GISTs, low CD133 methylation degree was correlated with a shorter disease-free survival.
Conclusions:
Our results strongly suggest epigenetic regulation of CD133 expression by promoter methylation in GISTs. Pending further validation studies, high abundance of the protein can serve as a marker for malignant GISTs.
Although known only since a few decades, gastrointestinal stromal tumors (GISTs) have become the most common mesenchymal tumors of the gastrointestinal tract. This tumor entity is proposed to arise from interstitial cells of Cajal, which are pacemaker cells in the myenteric plexus. The expression of stem cell markers KIT (CD117) and/or CD34 is a hallmark of GISTs. 1 Most of these tumors harbor a constitutively activating mutation of tyrosine kinase receptors KIT or, less commonly, PDGFRA. 2 These mutant transmembrane receptors can be targeted sufficiently by tyrosine kinase inhibitors such as imatinib. BRAF mutations are described only in single cases, and GISTs lacking known mutations of KIT/PDGFRA and BRAF count as wild-type and frequently harbor a deficiency in the succinatedehydrogenase complex. 3 Despite the striking therapeutic progress by targeted therapy, predicting the biological behavior of GISTs-which Upon completion of this activity you will be able to:
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can range from benign to highly aggressive-is still a diagnostic challenge. Several scores have been created for risk estimation, in consideration of tumor size and site, mitotic count, and proliferation index. 1, 4, 5 However, limitations exist in current risk stratification schemes, and evaluation of alternative prognostic markers is desirable. Expression of CD133 has been reported to be associated with gastric location and poor prognosis in GISTs. 6, 7 Shmelkov and coworkers 8 proved by using in vitro methylated reporter constructs epigenetic regulation of CD133 expression by the gene's promoter methylation in human Caco-2 cells. CD133, also known as prominin 1 or AC133, is a pentaspan transmembrane glycoprotein that has been initially described as a hematopoietic stem cell marker. 9 In a wide variety of tumor entities-including carcinomas of the colorectum, stomach, and pancreas; melanomas; brain tumors; and sarcomas-CD133 has been considered a marker for cancer stem cells. 10 CD133 expression has been correlated to adverse cancer properties such as metastasis, recurrence, and therapy resistance. [11] [12] [13] [14] In this context, upregulation of CD133 might also be associated with a more aggressive phenotype in GISTs. The aim of our study was to further elucidate the marker potential of CD133 in GISTs by focusing on the interrelationship between the gene's DNA methylation degree and its expression, along with anatomic location and mutation status.
Materials and Methods

Patients and Tumors
From a large ongoing study, we collected 95 consecutive GISTs, which were surgically resected between 1992 and 2010. Routinely processed paraffin-embedded tumor samples were derived from the Institutes of Pathology in Karlsruhe (50 cases) and Freiburg (45 cases), Germany. The patients were not treated by either targeted therapy or chemotherapy before operation. The age of the 39 male and 56 female patients ranged between 32 and 89 years (median, 68 years). In each case, diagnosis of GIST was confirmed by two senior pathologists (A.A. and F.H.) by morphological, immunohistochemical, and molecular analyses, as described elsewhere. 15 Most GISTs arose from the stomach (67.3%), followed by the ileum and jejunum (19.0%). The remaining cases were found in the duodenum (6.3%), rectum (5.3%), and colon (2.1%). More than half of all cases displayed a spindle cell morphology (56.8%), while epithelioid and mixed growing patterns were present in 15.8% and 27.4%, respectively. The mean tumor size was 5.8 cm, ranging from 0.4 to 25 cm. Eighteen GISTs measured less than 2 cm, 38 GISTs were between 2 and 5 cm, 24 GISTs were between 5 and 10 cm, and 15 GISTs were more than 10 cm.
Activating mutations of the KIT gene were detected in 75.8% cases that were mostly located in exon 11 (88.5%). Exon 9 and exon 13 were affected in 9.4% and 2.1%, respectively. Fourteen (14.7%) of 95 GISTs harbored mutations of PDGFRA that were present in exons 18 (78.6%) and 12 (21.4%). Only a single case with a BRAF mutation was identified. The remaining eight (8.4%) cases were considered wild-type.
Applying the prognostic score according to Fletcher et al, 1 Characteristics of patients and tumors are summarized in Table 1 . This study and the related translational research activities are covered by a positive ethics vote of the ethics committee of the Albert-Ludwigs University Freiburg (no. 81/ 11; date: March 3, 2011).
Tissue Microarrays and Immunohistochemistry
Tissue microarrays (TMAs) were designed as earlier reported. 17 Two to four punches were available for each case.
One complete and tumor-bearing core per case was regarded as sufficient for evaluation. Freshly cut TMA slides were stained according to a standard immunohistochemical protocol in the Autostainer Plus instrument (Dako, Hamburg, Germany). The monoclonal antibody (CD133/1; MACS, Bergisch Gladbach, Germany) was applied in a 1:100 dilution. Positive and negative controls were included into each run. CD133 abundance in GISTs was determined by a senior pathologist (H.G.) blinded for clinicopathologic data. Cytoplasmic staining intensity of tumor cells was determined semiquantitatively, and one of the following scores was assigned to each sample: 0 ¼ negative, 1 ¼ weak, 2 ¼ moderate, and 3 ¼ strong expression. In cases with inhomogeneous staining, the strongest intensity was chosen for assessment regardless of cell proportion. In a second round, all punches were reevaluated within the assigned group to ensure reliable results. GIST specimens were considered CD133 positive if immunohistochemical staining was moderate (immunohistochemistry [IHC] score 2) or strong (IHC score 3).
DNA Isolation, Bisulfite Treatment, and Polymerase Chain Reaction Amplification DNA was extracted from the samples using the QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany) as suggested by the manufacturer. DNA concentration was measured in an ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE). Extracted DNA samples were treated with sodium bisulfite as described earlier. 18 A total of 500 ng DNA was treated with sodium 
Bisulfite Pyrosequencing
A volume of 20 mL of each PCR product was mixed with 2 mL Streptavidin Sepharose High Performance (GE Healthcare, Uppsala, Sweden), 38 mL PyroMark binding buffer (Qiagen), and 10 mL water. The PyroMark Q24 Vacuum Workstation (Qiagen) was used to prepare single-stranded DNA. The Sepharose beads with the single-stranded templates attached were released into a PyroMark Q24 Plate (Qiagen) containing 25 mL of 0.3 lmol/L corresponding sequencing primer in annealing buffer. Pyrosequencing reactions were carried out using the PyroMark Gold Q24 Reagents (Qiagen) in a PyroMark Q24 Pyrosequencing System (Qiagen) according to the manufacturer's protocol. Quantification of CpG methylation was performed using the software PyroMark Q24 v.2.0.6 (Qiagen). The slight amplification bias toward unmethylated alleles was corrected using the calibration data derived from a set of control samples and cubic polynomial regression as previously described. 19 
Cell Culture and Messenger RNA Expression
The human cell lines GIST882 and GIST48b were grown in Roswell Park Memorial Institute 40 medium (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin (Life Technologies). To determine whether CD133 expression could be restored upon hypomethylation, cells were cultivated in media that were supplemented with 0, 10, 25, 50, 100, and 500 nmol/L 5-aza-2 0 -deoxycytidine (5-aza-dC).
Total RNA was isolated using the miRNeasy Mini Kit (Qiagen) as suggested by the manufacturer. The RNA concentration was measured in an ND-1000 spectrophotometer (Thermo Scientific). Reverse transcription reactions were carried out with 1 mg total RNA using the QuantiTect Reverse Transcription Kit (Qiagen). Quantitative reverse transcriptase PCR was performed in triplicate with the 7500 Fast Real-Time PCR System (ABI, Foster City, CA) using the QuantiTect SYBR Green PCR Kit and PROM1 QuantiTect Primer assay (both from Qiagen).
Statistical Analysis
Statistical analysis was performed by using the SPSS statistics 19 software (IBM, Ehningen, Germany). Methylation percentages and clinicopathologic characteristics were analyzed by the v 2 test. Immunohistochemical data were evaluated using the t test. Disease-free survival rates were plotted by the Kaplan-Meier method.
Associations of patient and tumor variables with survival times were assessed with the log-rank test. P < .05 was considered statistically significant.
Results
CD133 Is Hypermethylated in GIST Cell Lines and Reactivated Upon Demethylation With 5-aza-dC
To ascertain if the expression of CD133 in GISTs may be regulated by DNA methylation, the two cell lines, GIST48b and GIST882, were studied first. Bisulfite pyrosequencing was employed to interrogate the methylation status of a single CpG dinucleotide upstream of the gene's transcriptional start site CD133_-44. A high degree of methylation was recorded in GIST48b and GIST882 cells-namely, 74% and 60%, respectively. To test the functionality of the gene's hypermethylation, messenger RNA (mRNA) abundance was quantified using quantitative PCR after treatment with increasing concentrations of DNA demethylating agent 5-aza-dC. In cell line GIST48b, the drug induced gradual CD133 demethylation down to 34% at a 5-aza-dC concentration of 500 nmol/L with concomitant reactivation of the gene's expression up to 126-fold, suggesting the role of hypermethylation in silencing of the gene in this cell line model Figure 1 .
CD133 Is Differentially Methylated and Expressed According to Tumor Size, Suggesting the Role in GIST Progression
Given that DNA methylation in established tumor cell lines may not always adequately reflect primary tumors, patients' GIST samples were interrogated next. Overall, a mean CD133 DNA methylation percentage of 47.6% was documented across a total of 95 GIST specimens, indicating that the gene's hypermethylation is characteristic of primary tumors, too. We next stratified our sample set according to tumor sizes and assessed CD133 methylation percentage in each group. Markedly different CD133 DNA methylation load reflected different tumor sizes. Specifically, while the highest (median of 68%) methylation percentage was documented in small tumors below 2 cm, this epigenetic mark was virtually undetectable (median of 11%) in large GISTs of more than 10 cm. Intermediate CD133 methylation percentages (medians of 60% and 38%) were detected in medium-sized tumors of 2 to 5 cm and 5 to 10 cm, respectively (P < .01) Figure 2A . Collectively, these observations suggest the gradual decrease of CD133 degree as tumors progress. To further ascertain if CD133 DNA methylation affects the expression of the gene, the expression of CD133 was semiquantitatively evaluated by means of immunohistochemical staining. Importantly, the protein abundance correlated inversely with the percentage of CD133 methylation Figure 2B . Specifically, the highest (54%) portion of interrogated cases with an IHC score of 3 (strongly positive) was characteristic of large GISTs (>10 cm) with the lowest methylation degree. In contrast, only 5.3% of specimens with an IHC score of 3 were documented in a subgroup of small (<2 cm) tumors that featured hypermethylation of the gene. Representative results of immunohistochemical staining for CD133 are summarized in Image 1 . Taken together, a stepwise decrease of CD133 methylation level and concurrent augmentation of the protein abundance correlated with the growing tumor size despite the anatomic location (P < .01). A strong inverse correlation of the CD133 methylation and expression data sets further suggests the role of the gene's methylation in the pathogenesis of GISTs.
CD133 Is Differentially Methylated and Expressed in GISTs That Arise in Different Portions of Gastrointestinal Tract and Harbor Distinct Initiating Mutations
Given the predictive potential of the anatomic location of GISTs, we further stratified our cohort according to organs of tumor origin and corresponding activation mutations. The subgroups included KIT-mutant GISTs from the stomach, small intestine (duodenum, jejunum, and ileum), and large intestine (colon and rectum); PDGFRA-mutant gastric GISTs; one BRAF-mutant tumor; and wild-type GISTs. Differential CD133 methylation was observed in the interrogated groups Figure 3A . Specifically, wild-type GISTs were characterized by the highest CD133_-44 methylation level (median of 94%). KIT-mutant GISTs from the small and large intestine exhibited a high (medians of 82% and 63%, respectively) methylation percentage, too, whereas CD133 hypomethylation (median of 14%) was detected in gastric tumors that harbored KIT mutations. Interestingly, another subgroup of gastric GISTs with PDGFRA mutations clearly exhibited CD133 hypermethylation with a median value of 77%.
Unequal expression of CD133 was documented in the compared groups Figure 3B . Overall, the expression level was associated with the methylation status of the gene. While none of the PDGFRA-mutant tumors were characterized by moderate (IHC score 2) or strong (IHC score 3) staining, most (66.7%) KIT-mutant GISTs exhibited a strong or moderate immunohistochemical reaction. The proportion of cases with negative (IHC score 0), weak (IHC score 1), moderate (IHC score 2), and strong (IHC score 3) staining showed significant differences when correlated to both site of origin and driver mutation in GISTs Figure 3B (P < .01).
High CD133 Expression and Hypomethylation Status Predict Shorter Disease-Free Survival of Patients With GIST
Given the association of both CD133 methylation status and the gene's expression with tumor size and anatomic location, we asked if these could be considered potential molecular prognosticators for survival in GISTs. We used survival data that were available approximately in half of the patients (48 of 95) and performed a Kaplan-Meier survival analysis. CD133 expression was considered first. A group of patients with strong IHC staining for CD133 in GISTs (score 3) was compared with a group with low or moderate CD133 expression (scores 0-2). Disease-free survival was clearly shorter in the group with high CD133 expression (P ¼ .007; Figure 4A ).
Similarly, the patient cohort was stratified into two subgroups with CD133 methylation degree lower and higher than the respective mean value. Patients with a lower CD133 methylation percentage tended to have shorter disease-free survival, but this did not reach statistical significance, most likely owing to the limited sample size. In contrast, significantly shorter disease-free survival was observed in the subgroup of KIT-mutant gastric GISTs (n ¼ 48) with a low-level methylation (P ¼ .046; Figure 4B ). We next compared CD133 expression and the methylation status with the existing risk stratification criteria of GISTs. To this end, we also performed Cox regression analysis by using variables of tumor size, mitotic count, and CD133 expression. No improvement was observed, however, in the prediction of disease-free survival if the interrogated gene was taken into consideration.
Discussion
The concept of cancer stem cells has a lasting effect on our understanding of tumor biology. Many enigmatic but clinically important phenomena can be explained by this concept such as late-onset metastasis, recurrence, or therapy resistance. Epigenetic silencing of genes that are involved in maintenance of stem cell properties is impaired in tumor development and may lead to aberrant reactivation of expression. Such abnormally expressed proteins may serve as tumor markers. Reliable stem cell markers can both predict a patient's prognosis and be a helpful tool in the pathologic diagnosis of tumor entities that lack clear benign and malignant histologic features, for example, GISTs. Several risk stratification schemes have been proposed for GISTs with tumor size, anatomic site of origin, mitotic count, and proliferation index as main components. Despite their wide application in routine diagnostics, risk estimation in an individual case remains challenging. In this context, establishment of additional prognosticators would be desirable with several molecular markers that have been examined, including p53, p16, and p27. 20 However, these proteins are associated with proliferation, which is already included in the existing risk stratification schemes. In this study, we examined a stem cell marker CD133 that is not directly associated with any of the parameters constituting the current prognostication schemes in GISTs. Apart from evaluation of CD133 biomarker potential, this study aimed at understanding the regulation of CD133 expression in GISTs. We have shown that methylation of a CpG site CD133_-44 upstream of the gene's coding sequence is a frequent epigenetic event in both cell line models of GISTs and primary tumors. Markedly different CD133 DNA methylation percentages were documented in distinct clinicopathologic subtypes of the disease that exhibited a clear inverse correlation with CD133 protein abundance. In addition, induction of DNA hypomethylation with an inhibitor of DNA methyltransferases (5-aza-dC) in cell line GIST48b resulted in the pronounced reactivation of CD133 expression. Taken together, these data strongly suggest the epigenetic control of CD133 expression in GISTs by DNA methylation. These findings are concordant with earlier reports on different tumor entities. [21] [22] [23] For example, the extensive control of CD133 expression at multiple steps has been reported, including transcriptional regulation, alternative transcription initiation sites, alternative splicing, and posttranslational modifications. 8, 24 In our study, low CD133 DNA methylation level and high abundance of the protein were significantly associated with larger tumor size and, most important, with shorter disease-free survival. In gastric GISTs, the CD133 methylation status clearly discriminated KIT-mutant and PDGFRA-mutant GISTs. Our findings suggest a further subdivision of the existing groups of GISTs that are established according to driver mutations in KIT, PDGFRA, or BRAF by taking epigenetic alterations into consideration. Since the type of driver mutation cannot explain the diverse clinical course, the identification of differentially methylated candidates such as CD133 provide insights into GIST biology and may serve as molecular markers. In fact, aberrant DNA methylation of several genes (eg, p16) has been associated with more aggressive course and poorer prognosis. 25 Our results have been corroborated by several earlier reports. Specifically, the data on abundance of CD133 protein in GIST specimens are in full agreement with results of a large Swedish study. 6 Likewise, CD133 expression was associated with gastric location, KIT mutations, and poor prognosis. Although a Chinese study on 114 GISTs showed the same association of CD133 expression with gastric location and KIT mutations, no influence on relapse-free survival has been revealed. 20 In contrast, Chen et al 26 reported
that CD133 was universally overexpressed in GISTs and therefore could represent a marker of lineage differentiation rather than a stem cell marker. Still, a significant overexpression of CD133 was detected in gastric compared with small intestinal GISTs and in KIT-mutant vs PDGFR-mutant tumors, which is comparable with our results. Interestingly, our findings are in agreement with studies on other tumor entities, too-for example, glioma, where an inverse correlation between the gene's hypomethylation and high CD133 expression has been described. 27 Discrepancies in reports from different working groups may at least in part be explained methodologically. The choice of different sources of tumor cells (namely, freshfrozen or paraffin-embedded tissue), cell lines, and circulating tumor cells, along with different experimental approaches (analysis of DNA methylation, mRNA, or protein expression) and different techniques (in situ hybridization, immunohistochemical staining, or employment of animal models), are a plausible explanation for varying results.
Most studies emphasize the adverse role of CD133 in GISTs. 10 The identification of patients with aggressive tumors is crucial and of high clinical relevance. The pathologic diagnosis of malignant GIST remains challenging since lack of CD117 or CD34 expression is often revealed in tumors. CD133 hypomethylation and augmented protein expression can sufficiently aid in detecting the malignant potential of GISTs. The prognostic impact of CD133 is reflected by the significantly worse disease-free survival in patients with strong expression and hypomethylation of the gene. The adverse prognostic impact of high CD133 expression was proven in different cancer types-namely, colorectal, hepatocellular, and gastric carcinomas and sarcomas. 14, [28] [29] [30] Since downregulation of CD133 significantly reduces cell growth, migration, and invasive properties in vitro, it represents a promising therapeutic target, too. 31 Consistently, considerable effort has been made in the past years to introduce CD133 in targeted therapies. Promising results could be achieved both in vitro and in vivo for a wide variety of tumor entities, including carcinomas, gliomas, and melanomas. [32] [33] [34] [35] [36] [37] In this context, CD133 was suggested as a marker for chemoresistance in breast cancer and ovarian cancer. 22, 38 Deng et al 39 reported on biomarker utility of CD133 mRNA from peripheral blood of patients with GISTs for both imatinib resistance and disease progression. These reports warrant further investigations on CD133 as a therapeutic target in GISTs.
Taken together, our results strongly suggest the epigenetic mechanism of CD133 regulation by promoter methylation in GISTs. CD133 hypomethylation that is associated with high gene expression is a prognostically adverse finding. Pending further studies, high abundance of the protein can serve as a marker for malignant GISTs. In addition to its role as a diagnostic tool, CD133 could be considered a prospective molecular target for targeted therapy of GISTs.
